Treatments

Weight-Based Dosing of Clindamycin and TMP/SMX Improves Cellulitis Outcomes

Weight-Based Dosing of Clindamycin and TMP/SMX Improves Cellulitis Outcomes

By

Weight-based dosing options for treatment may improve clinical outcomes in patients with cellulitis.

Latent Tuberculosis May Benefit From 3-Month Rifapentine, Isoniazid Tx

Latent Tuberculosis May Benefit From 3-Month Rifapentine, Isoniazid Tx

By

Three months of rifapentine + isoniazid using directly observed therapy resulted in a higher completion rate and no loss of follow-up for latent tuberculosis.

Efficacy of Ravidasvir Plus Sofosbuvir for Chronic Hepatitis C Genotype 4

Efficacy of Ravidasvir Plus Sofosbuvir for Chronic Hepatitis C Genotype 4

By

Researchers believe new once-daily dose of ravidasvir plus sofosbuvir is effective in treatment HCV genotype-4 and may be cost effective.

Challenges in Multidrug-Resistant HIV Management: Ibalizumab Safe, Effective

Challenges in Multidrug-Resistant HIV Management: Ibalizumab Safe, Effective

By

Ibalizumab may be a valuable option in patients with multidrug-resistant HIV.

Examining Drug-Drug Interactions in Women With HIV: ART and Hormonal Contraception

Examining Drug-Drug Interactions in Women With HIV: ART and Hormonal Contraception

By

Examining the barriers to co-use of hormonal contraceptives and antiretroviral therapy in women with HIV.

New Guidelines Show Best Practices for <i>H pylori</i> Treatment

New Guidelines Show Best Practices for H pylori Treatment

By

Three new guidelines discuss the best practice for Helicobacter pylori treatment.

Metformin Reduces Mortality During Tuberculosis Therapy

Metformin Reduces Mortality During Tuberculosis Therapy

By

Researchers assess all-cause mortality during tuberculosis treatment in patients with diabetes, the use of metformin, and effect sputum culture-conversion rates.

Direct-Acting Antivirals: The Gold Standard for HCV Recurrence Following Transplantation?

Direct-Acting Antivirals: The Gold Standard for HCV Recurrence Following Transplantation?

By

The majority of patients treated with second-generation direct-acting antiviral agents achieved sustained virologic response in 12 weeks.

Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit

Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit

By

Primary endpoints are to achieve sustained virologic response, improve survival rates, and lower complications of HCV.

Development Program for Hepatitis C Treatments Discontinued

Development Program for Hepatitis C Treatments Discontinued

By

Merck announced that the development programs for two hepatitis C virus infection treatments have been discontinued.

IV Penicillin Safety in Those With Allergy History But Negative Skin Test

IV Penicillin Safety in Those With Allergy History But Negative Skin Test

By

Repeated intravenous administration of penicillin antibiotics appears to be safe in patients with a reported penicillin allergy and a negative penicillin allergy test.

Ribaxamase May Prevent Opportunistic Infections During IV β-lactam Treatment

Ribaxamase May Prevent Opportunistic Infections During IV β-lactam Treatment

By

SYN-004, ribaxamase, is an oral B-lactamase medication to be combined with intravenous β-lactam antibiotics to prevent disruption of the gut microbiome.

Macrolides Superior to Beta-Lactams in Pediatric Community-Acquired Pneumonia

Macrolides Superior to Beta-Lactams in Pediatric Community-Acquired Pneumonia

By

Macrolides, despite inferior anti-pneumococcal activity, are the most commonly prescribed antibiotic class for CAP in Children.

Delafloxacin: Tolerable, Effective Against Gram-Negative Pathogens for ABSSSI

Delafloxacin: Tolerable, Effective Against Gram-Negative Pathogens for ABSSSI

By

Delafloxacin is effective against gram-negative pathogens and has a similar tolerability profile to vancomycin/aztreonam when used in patients with an ASSSSI.

Delafloxacin is Effective, Safe for MRSA Treatment in ABSSSI

Delafloxacin is Effective, Safe for MRSA Treatment in ABSSSI

By

Fixed dose delafloxacin IV/oral monotherapy was comparable to vancomycin/aztreonam in patients with ABSSSI and gram-positive pathogens.

Ridinilazole Preserves Gut Microbiome Diversity in Treatment of <i>C difficile</i> Infection

Ridinilazole Preserves Gut Microbiome Diversity in Treatment of C difficile Infection

By

Compared with fidaxomicin, ridinilazole preserved gut microbiome diversity to a greater extent in the treatment of Clostridium difficile infection.

No Difference in Adverse Events Between Delafloxacin or Vancomycin/Aztreonam in ABSSSI

No Difference in Adverse Events Between Delafloxacin or Vancomycin/Aztreonam in ABSSSI

By

Incidence of adverse events with delafloxacin (Baxdela™, Melinta Therapeutics) was comparable to the combination regimen of vancomycin plus aztreonam across 2 phase 3 registrational ABSSSI studies.

Once-Daily Treatment Regime for Hepatitis C With Compensated Cirrhosis

Once-Daily Treatment Regime for Hepatitis C With Compensated Cirrhosis

By

Researchers assessed safety and tolerability throughout the 12 week study period and 24 weeks after completion of last dose of glecaprevir coformulated with pibrentasvir.

Does Sustained Virologic Response Improve Glycemic Control in HCV?

Does Sustained Virologic Response Improve Glycemic Control in HCV?

By

Researchers compared HbA1c changes and use of antidiabetic medication in HCV with diabetes.

Guideline-Adherent Antibiotics Decrease Readmission for Acute Chest Syndrome

Guideline-Adherent Antibiotics Decrease Readmission for Acute Chest Syndrome

By

Researchers believe implementation of treatment guidelines for children with sickle cell disease with acute chest syndrome may decrease hospital readmission rates.

FDA Approval: Single-Dose Oral Therapy for Bacterial Vaginosis

FDA Approval: Single-Dose Oral Therapy for Bacterial Vaginosis

By

The FDA has approved the first oral treatment for bacterial vaginosis.

Once-Daily Single-Tablet HIV Treatment Safe, Effective in Children

Once-Daily Single-Tablet HIV Treatment Safe, Effective in Children

By

The single tablet regimen is a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.

FDA Announces Orphan Drug Designation for HDV Drug

FDA Announces Orphan Drug Designation for HDV Drug

By

The Orphan Drug Designation Program offers orphan status to biologics and drugs that are safe and effective for rare diseases; also for prevention use.

Dexamethasone Reduces Need for Antibiotics in Adults With Sore Throat

Dexamethasone Reduces Need for Antibiotics in Adults With Sore Throat

By

Looking for a way to reduce inappropriate antibiotic use for adults with acute sore throats, researchers evaluated whether as single dose of oral corticosteriod can effectively reduce likelihood of symptom resolution.

HCC Risk After HCV Direct-Acting Antiviral Treatment

HCC Risk After HCV Direct-Acting Antiviral Treatment

By

The occurrence or recurrence risk for hepatocellular carcinoma is unclear after direct-acting antiviral agents and interferon based therapy.

Respiratory Syncytial Virus Treatment Development Discontinued

Respiratory Syncytial Virus Treatment Development Discontinued

By

Regeneron discontinued further development of suptavumab for respiratory syncytial virus.

Update on Pediatric HCV: Screening, Treatment, and Other Considerations

Update on Pediatric HCV: Screening, Treatment, and Other Considerations

By

Experts discuss screening, treatment, and other considerations in pediatric HCV.

Time to Sputum Culture Conversion Similar in Isoniazid-Resistant and Susceptible TB

Time to Sputum Culture Conversion Similar in Isoniazid-Resistant and Susceptible TB

By

A new study examined whether isoniazid resistance was associated with variations in treatment outcomes in patients receiving standard first-line pharmacotherapy for TB.

Tympanogram Results May Guide Appropriate Use of Abx in Acute Otitis Media

Tympanogram Results May Guide Appropriate Use of Abx in Acute Otitis Media

Older age and peaked tympanogram are associated with reduced risk of treatment failure in young children with acute otitis media.

Hepatitis B: Search for the Cure and Challenges That Remain

Hepatitis B: Search for the Cure and Challenges That Remain

By

One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access to suitable treatment.

Sign Up for Free e-newsletters